Toll-like receptors in ovarian cancer as targets for immunotherapies

Frontiers in Immunology

Volumn 5, Issue JUL, 2014, Pages

  Muccioli, Maria ^a   Benencia, Fabian ^a,b  

^a OHIO UNIVERSITY   (United States)

^b OHIO UNIVERSITY   (United States)

Author keywords

Immunotherapy; Ovarian cancer; Pattern recognition receptors; Toll like receptors; Tumor microenvironment

Indexed keywords

EID: 84905653969     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00341     Document Type: Short Survey

References (57)

1. Cannistra SA. Cancer of the ovary. N Engl J Med (2004) 351:2519-29. doi: 10.1056/NEJMra041842
2. Auersperg N, Wong A, Choi K, Kang S, Leung P. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev (2001) 22:255-88. doi:10.1210/er.22.2.255
3. Bast RCJ, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9:415-28. doi:10.1038/nrc2644
4. NCI. Seer Stat Fact Sheet: Ovary Cancer; 2003-2009; Surveillance Research Program, N. (ed.) (2013).
5. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res (2001) 7:2168-81.
6. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev (2006) 6:24-7. doi:10.1038/nrc1782
7. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nature (2012) 12:9. doi:10.1038/nrc3245
8. Nelson D, Ganss R. Tumor growth or regression: powered by inflammation. J Leukoc Biol (2006) 80:685-90. doi:10.1189/jlb.1105646
9. Schreiber R, Old L, Smyth M. Cancer immunoediting: integrating immunity's roles in cancer suppression and progression. Science (2012) 331:1565-70. doi:10.1126/science.1203486
10. Benencia F, Muccioli M, Alnaeeli M. Perspectives on reprogramming cancer-associated dendritic cells for antitumor therapies. Front Oncol (2014) 4:72. doi:10.3389/fonc.2014.00072
11. Scarlett U, Cubillos-Ruiz JR, Nesbeth Y, Martinez D, Fields J, Gewitz A, et al. Immunosuppressive ovarian cancer-infiltrating dendritic cells can be transformed into immunostimulatory cells through in situ CD40 and toll-like receptor 3 stimulation. Immunology (2010) 184:100.32.
12. Lavoue V, Thedrez A, Leveque J, Foucher F, Henno S, Jauffret V, et al. Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med (2013) 11:1-12. doi:10.1186/1479-5876-11-147
13. Cubillos-Ruiz JR, Rutkowski M, Conejo-Garcia JR. Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle (2010) 9:260-8. doi:10.4161/cc.9.2.10430
14. Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang JM. Toll-like receptors in inflammation, infection, and cancer. Int Immunopharmacol (2007) 7:13. doi:10.1016/j.intimp.2007.05.016
15. Chen R, Alvero AB, Silasi DA, Steffensen KD, Mor G. Cancers take their toll - the function and regulation of toll-like receptors in cancer cells. Oncology (2008) 27:225-33. doi:10.1038/sj.onc.1210907
16. Chen R, Alvero AB, Silasi D-A, Mor G. Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol (2007) 57:93-107. doi:10.1111/j.1600-0897.2006.00441.x
17. Goutangy N, Estornes Y, Hasan U, Lebecque S, Caux C. Targeting pattern recognition receptors in cancer immunotherapy. Target Oncol (2012) 7:29-54. doi:10.1007/s11523-012-0213-1
18. Yu L, Chen S. Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother (2008) 57:1271-8. doi:10.1007/s00262-008-0459-8
19. Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S, et al. Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res (2010) 70:11. doi:10.1158/0008-5472.CAN-09-1890
20. Underhill DM. Toll-like receptors: networking for success. Eur J Immunol (2003) 33:9. doi:10.1002/eji.200324037
21. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol (2001) 8:675-80. doi:10.1038/90609
22. Takeda K, Akira S. TLR signaling pathways. Semin Immunol (2004) 16:3-9. doi:10.1016/j.smim.2003.10.003
23. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol (2003) 21:42. doi:10.1146/annurev.immunol.21.120601.141126
24. Scarlett UK, Cubillos-Ruiz JR, Nesbeth Y, Martinez D, Engle X, Gewirtz AT, et al. In situ stimulation of CD40 and toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res (2009) 69:7329-37. doi:10.1158/0008-5472.CAN-09-0835
25. Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J, et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med (2012) 209:495-506. doi:10.1084/jem.20111413
26. Zhou M, Macfarland-Mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF. Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother (2009) 58:1375-85. doi:10.1007/s00262-008-0650-y
27. Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, et al. Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer (2010) 116:9. doi:10.1002/cncr.25190
28. Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM. Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res (2010) 70:10. doi:10.1158/0008-5472.CAN-09-3912
29. Sato Y, Goto Y, Narita N, Hoon DS. Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenviron (2009) 2:205-14. doi:10.1007/s12307-009-0022-y
30. Ruegg C. Leukocytes, inflammation, and angiogenesis in cancer: fatal attractions. J Leukoc Biol (2006) 80:682-4. doi:10.1189/jlb.0606394
31. Conejo-Garcia JR, Benencia F, Couregges MC, Kang E, Mohamed-Hadley A, Bukanovich R, et al. Tumor-infiltrating dendritic cell precursors recruited by β-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med (2004) 10:950-8. doi:10.1038/nm1097
32. Conejo-Garcia JR, Buckanovich RJ, Benencia F, Courreges MC, Rubin SC, Carroll RG, et al. Vascular leukocytes contribute to tumor vascularization. Blood (2005) 105:679-81. doi:10.1182/blood-2004-05-1906
33. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell (2010) 140:883-99. doi:10.1016/j.cell.2010.01.025
34. Morse MA, Chapman R, Powderly J. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin Cancer Res (2011) 17:4844-53. doi:10.1158/1078-0432.CCR-11-0891
35. Adams M, Navabi H, Croston D, Coleman S, Tabi Z, Clayton A, et al. The rationale for combined chemo/immunotherapy using a toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine (2005) 23:2374-8. doi:10.1016/j.vaccine.2005.01.014
36. Bellora F, Castriconi R, Dondero A, Pessino A, Nencioni A, Liggieri G, et al. TLR activation of tumor-associated macrophages from ovarian cancer patients triggers cytolytic activity of NK cells. Eur J Immunol (2014) 6:1814-22. doi:10.1002/eji.201344130
37. Heusinkveld M, van der Burg S. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med (2011) 9:1-13. doi:10.1186/1479-5876-9-216
38. Brueseke TJ, Tewari KS. Toll-like receptor 8: augmentation of innate immunity in platinum-resistant ovarian carcinoma. Clin Pharmacol (2013) 5:13-9. doi:10.2147/CPAA.S40401
39. Cohen PA, Northfelt DW, Weiss GJ, Von Hoff DD, Manjarrez G, Dietsch G, et al. Phase I clinical trial of VTX-2337, a selective TLR8 agonist, in patients with advanced solid tumors. J Clin Oncol (2011) 29:2557.
40. Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science (2005) 309:1380-4. doi:10.1126/science.1113401
41. Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist (2008) 13:859-75. doi:10.1634/theoncologist.2008-0097
42. Lu H, Dietsch GN, Matthews MH, Yang Y, Ghanekar S, Inokuma M, et al. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res (2012) 18:499-509. doi:10.1158/1078-0432.CCR-11-1625
43. Geller MA, Cooley S, Argenta PA, Downs L, Carson LF, Judson PL, et al. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol Immunother (2010) 59:1877-84. doi:10.1007/s00262-010-0914-1
44. Chuang CM, Monie A, Wu A, Mao CP, Hung CF. Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum Gene Ther (2009) 20:303-13. doi:10.1089/hum.2008.124
45. Huang B, Zhao J, Li H, He K, Chen Y, Mayer L, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res (2005) 65:5009-14. doi:10.1158/0008-5472.CAN-05-0784
46. Kelly MG, Alvero AB, Chen R, Silasi D, Abrahams VM, Chan S, et al. TLR4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res (2006) 66:10. doi:10.1158/0008-5472.CAN-05-3948
47. Woods DC, White YA, Dau C, Johnson AL. TLR4 activates NF-KB in human ovarian granulosa tumor cells. Biochem Biophys Res Commun (2011) 409:675-80. doi:10.1016/j.bbrc.2011.05.063
48. Berger R, Fiegl H, Goebel G, Obexer P, Ausserlechner M, Doppler W, et al. Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci (2010) 101:1059-66. doi:10.1111/j.1349-7006.2010.01491.x
49. Karin M, Cao Y, Greten FR, LI Z. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev (2002) 2:301-10.
50. Yu L, Wang L, Chen S. Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med (2010) 14:2592-603. doi:10.1111/j.1582-4934.2010.01127.x
51. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: endogenous danger signaling. Mol Med (2008) 14:476-84. doi:10.2119/2008-00034.Klune
52. Cheng N, He R, Tian J, Ye PP, Ye RD. Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol (2008) 181:22-6. doi:10.4049/jimmunol.181.1.22
53. Sandri S, Rodriguez D, Gomes E, Monteiro H, Russo M, Campa A. Is serum amyloid A and endogenous TLR4 agonist? J Leukoc Biol (2008) 88:1174-80. doi:10.1189/jlb.0407203
54. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene (2008) 27:218-24. doi:10.1038/sj.onc.1210904
55. Killeen SD, Wang JH, Andrews EJ, Redmond HP. Exploitation of the toll-like receptor system in cancer: a doubled-edged sword? Br J Cancer (2006) 95:247-52. doi:10.1038/sj.bjc.6603275
56. Chen R, Alvero AB, Silasi DA, Kelly MG, Fest S, Visintin I, et al. Regulation of IKKbeta by miR-199a addicts NF-kappaB activity in ovarian cancer cells. Oncogene (2008) 27:4712-23. doi:10.1038/onc.2008.112
57. O'Neill L, Sheedy FJ, Mccoy CE. MicroRNAs: the fine-tuners of toll-like receptor signaling. Nat Rev Immunol (2011) 11:163-75. doi:10.1038/nri2957